Apyx Medical Performance degli utili passati
Criteri Il passato verificati 0/6
Gli utili di Apyx Medical sono diminuiti a un tasso medio annuo di -1.2%, mentre il settore Medical Equipment ha visto gli utili crescere a un tasso medio annuo di 13.6%. I ricavi sono cresciuti crescere a un tasso medio annuo di 4.2%.
Informazioni chiave
-1.18%
Tasso di crescita degli utili
1.04%
Tasso di crescita dell'EPS
| Medical Equipment Crescita del settore | 8.90% |
| Tasso di crescita dei ricavi | 4.19% |
| Rendimento del capitale proprio | -69.35% |
| Margine netto | -16.40% |
| Ultimo aggiornamento sugli utili | 31 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento della narrazione • May 30
APYX: GLP 1 Skin Tightening Demand Will Drive Future Upside
Apyx Medical's analyst price target has shifted to $6.50 from $6.40, as analysts point to a higher Street target around $6; recent research highlighting stronger guidance into 2026; potential upside from liposuction handpiece approval; and growing international and GLP-1 related demand, alongside updated assumptions for slightly faster revenue growth, a lower discount rate, modestly lower profit margins, and a reduced future P/E multiple. Analyst Commentary Recent Street research highlights a mix of optimism and caution around Apyx Medical, with attention on execution against 2026 guidance, new products, and international expansion.Articolo di analisi • May 11
Earnings Update: Here's Why Analysts Just Lifted Their Apyx Medical Corporation (NASDAQ:APYX) Price Target To US$6.50
Apyx Medical Corporation ( NASDAQ:APYX ) investors will be delighted, with the company turning in some strong numbers...Aggiornamento della narrazione • May 05
APYX: GLP 1 Skin Tightening And New Tools Will Drive Upside
Analysts have raised their Apyx Medical price target to $6 from $5, citing a stronger recent quarter, higher 2026 guidance and added potential from new product approvals, geographic expansion and growing demand linked to GLP-1 usage. Analyst Commentary Bullish Takeaways Bullish analysts point to the recent quarter, where sales were in line and earnings were ahead of expectations, as support for a higher valuation framework.Aggiornamento della narrazione • Apr 21
APYX: GLP-1 Skin Tightening Demand Will Support Future Upside
Analysts have lifted their price targets on Apyx Medical to $6, up from $5, citing a strong quarter; 2026 guidance above prior Street expectations; early traction from the Ayon launch; and potential upside from new product approvals, GLP-1 related skin tightening demand, and international expansion. Analyst Commentary Bullish Takeaways Bullish analysts see the new $6 price target as reflecting stronger confidence in execution after a quarter where sales were in line and earnings were ahead of prior expectations, which they view as supportive for valuation.Aggiornamento della narrazione • Apr 05
APYX: GLP-1 Skin Tightening Trend Will Drive Future Upside
Narrative Update on Apyx Medical The updated analyst price target for Apyx Medical moves to $6, with analysts pointing to a strong quarter, 2026 guidance that is ahead of Street expectations, early traction from the Ayon launch, growing skin tightening demand linked to GLP-1 usage, and expansion opportunities outside the U.S. as key supports for the change. Analyst Commentary Recent Street research on Apyx Medical centers on a higher $6 price target and an upgrade to a more constructive stance, driven by operational updates, new product traction, and exposure to GLP-1 related demand trends.Aggiornamento della narrazione • Mar 22
APYX: GLP-1 Procedure Demand And International Expansion Will Drive Future Upside
Narrative Update: Apyx Medical Apyx Medical's updated fair value estimate edges up from $6.00 to $6.40 as analysts point to a higher Street price target of $6.00, recent earnings outperformance, 2026 guidance that sits above prior expectations, and additional growth opportunities tied to new product approvals, GLP-1 related demand, and international expansion. Analyst Commentary Recent Street commentary on Apyx Medical is broadly constructive, with analysts pointing to a combination of product momentum, new procedure use cases, and international expansion as key inputs to their updated valuation work.Aggiornamento della narrazione • Mar 06
APYX: Strong Revenue Outlook Will Support Future Single Platform Adoption
Analysts have raised their Apyx Medical price target to $6.00, up from $6.00, citing updated assumptions around revenue growth, profit margins, the discount rate and future P/E that together refine their view of the stock's risk and earnings potential. What's in the News Apyx Medical issued preliminary revenue guidance for fourth quarter 2025, with management expecting revenue between $19.0 million and $19.2 million, which the company states represents a 34% year over year increase (Key Developments).Aggiornamento della narrazione • Feb 19
APYX: Single Console Platform Will Drive Future Adoption And Margin Expansion
Analysts have modestly adjusted their price target framework for Apyx Medical, reflecting updated assumptions around profit margin and future P/E that contribute to a refined view of fair value at $6.00 per share. What's in the News Apyx Medical issued preliminary revenue guidance for the fourth quarter of 2025, with expected revenue between $19.0m and $19.2m, described by the company as approximately 34% year over year growth (company guidance).Aggiornamento della narrazione • Feb 03
APYX: Single Console Platform Will Drive Wider Adoption And Margin Expansion
Narrative Update on Apyx Medical Analysts have raised their price target on Apyx Medical to US$8, reflecting increased confidence that the AYON all in one console, which integrates Renuvion with additional surgical offerings, can attract physicians through its differentiated technology, workflow benefits, and broad patient appeal. Analyst Commentary Recent research updates are framing Apyx Medical as a company where expectations are increasingly tied to execution on the AYON platform and its potential impact on growth, margins, and valuation.Articolo di analisi • Feb 03
Subdued Growth No Barrier To Apyx Medical Corporation (NASDAQ:APYX) With Shares Advancing 26%
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...Aggiornamento della narrazione • Jan 20
APYX: Single Console Platform Will Support Future Procedure And Workflow Adoption
Analysts have raised their price target on Apyx Medical to $8, pointing to the AYON system's integrated console design, use of the legacy Renuvion technology, and its appeal to physicians as key supports for the updated view. Analyst Commentary Recent analyst commentary around Apyx Medical has focused on how the AYON system could influence the company’s growth path, execution risks, and valuation framework.Articolo di analisi • Jan 13
Is Apyx Medical Corporation (NASDAQ:APYX) Trading At A 45% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Apyx Medical fair value estimate is US$7.24 Apyx Medical is...Aggiornamento della narrazione • Jan 06
APYX: Single Console Platform Will Drive Future Procedure Adoption Upswing
Analysts have nudged their fair value target for Apyx Medical to $6.00 per share, citing greater confidence in the AYON system's all in one console design and its potential appeal to physicians and a broadening patient base. Analyst Commentary Bullish Takeaways Bullish analysts point to the AYON system's all in one, single console design as a core driver for their higher fair value targets, arguing that a unified platform can support more efficient procedure volumes and revenue per installed unit over time.Aggiornamento della narrazione • Dec 22
APYX: New Surgical Console Rollout Will Drive Stronger Demand Inflection
Analysts have modestly raised their price target on Apyx Medical to $8.00, citing increasing confidence that the AYON system can drive faster adoption and enhance the company’s long term growth and profitability profile. Analyst Commentary Analyst feedback on Apyx Medical has been largely constructive, with the AYON system viewed as a key catalyst for accelerating revenue growth and improving the company’s valuation profile.Aggiornamento della narrazione • Dec 08
APYX: Workflow Console Rollout Will Drive Bullish Demand Inflection
Analysts have raised their price target on Apyx Medical to $8.00, citing increasing optimism that the AYON all in one console, which integrates the company's Renuvion technology with multiple surgical offerings, can drive an inflection in demand by streamlining workflows and addressing a large, growing patient base. Analyst Commentary Recent research notes highlight a shift in sentiment as bullish analysts point to AYON as a key driver of Apyx Medical's next phase of growth, underpinning the higher price target.Aggiornamento della narrazione • Nov 24
APYX: Recent Product Launch and Equity Raise Will Drive Share Momentum
Analysts have raised their price target for Apyx Medical from $4.50 to $6.00 per share, citing increased growth prospects supported by the successful launch and strong physician appeal of the AYON system. Analyst Commentary Recent analyst feedback reflects a growing optimism around Apyx Medical's outlook, particularly in light of the momentum generated by the AYON system launch and its integration of legacy technology and new surgical offerings.Articolo di analisi • Nov 18
Apyx Medical Corporation's (NASDAQ:APYX) Shares Leap 38% Yet They're Still Not Telling The Full Story
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...Articolo di analisi • Nov 07
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
Apyx Medical Corporation ( NASDAQ:APYX ), is not the largest company out there, but it received a lot of attention from...Aggiornamento della narrazione • Nov 07
APYX: Earnings Guidance Increase Will Drive Market Expansion Opportunities
Narrative Update on Apyx Medical: Analyst Price Target Revision Analysts have raised their price target for Apyx Medical from $4.00 to $4.50 per share. This change is attributed to improved profitability and a lower discount rate, even though there is a reduction in projected revenue growth.Articolo di analisi • Oct 04
Even With A 26% Surge, Cautious Investors Are Not Rewarding Apyx Medical Corporation's (NASDAQ:APYX) Performance Completely
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders would be excited to see that the share price has had a great...Articolo di analisi • Sep 19
Is Apyx Medical (NASDAQ:APYX) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Jul 26
A Piece Of The Puzzle Missing From Apyx Medical Corporation's (NASDAQ:APYX) 34% Share Price Climb
Despite an already strong run, Apyx Medical Corporation ( NASDAQ:APYX ) shares have been powering on, with a gain of...Articolo di analisi • Apr 23
The Market Doesn't Like What It Sees From Apyx Medical Corporation's (NASDAQ:APYX) Revenues Yet As Shares Tumble 25%
To the annoyance of some shareholders, Apyx Medical Corporation ( NASDAQ:APYX ) shares are down a considerable 25% in...
Nuova narrazione • Apr 11
AYON Launch And Restructuring Will Create Lasting Opportunities
The launch of the AYON Body Contouring System may significantly drive revenue growth through market expansion and increased equipment sales.Articolo di analisi • Mar 05
Apyx Medical Corporation's (NASDAQ:APYX) Shares Lagging The Industry But So Is The Business
With a price-to-sales (or "P/S") ratio of 0.9x Apyx Medical Corporation ( NASDAQ:APYX ) may be sending very bullish...Articolo di analisi • Dec 19
Is Now The Time To Look At Buying Apyx Medical Corporation (NASDAQ:APYX)?
While Apyx Medical Corporation ( NASDAQ:APYX ) might not have the largest market cap around , it led the NASDAQGS...Articolo di analisi • Nov 23
Apyx Medical Corporation (NASDAQ:APYX) Surges 30% Yet Its Low P/S Is No Reason For Excitement
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders would be excited to see that the share price has had a great...Articolo di analisi • Sep 14
Is There An Opportunity With Apyx Medical Corporation's (NASDAQ:APYX) 41% Undervaluation?
Key Insights The projected fair value for Apyx Medical is US$1.98 based on 2 Stage Free Cash Flow to Equity Apyx...Articolo di analisi • Aug 07
Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Apyx Medical Corporation ( NASDAQ:APYX ) shareholders that were waiting for something to happen have been dealt a blow...Articolo di analisi • Aug 01
We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed
Key Insights Apyx Medical will host its Annual General Meeting on 8th of August Salary of US$482.5k is part of CEO...Articolo di analisi • Jun 19
Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Articolo di analisi • Apr 18
Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive
Unfortunately for some shareholders, the Apyx Medical Corporation ( NASDAQ:APYX ) share price has dived 25% in the last...Articolo di analisi • Mar 26
Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates
Market forces rained on the parade of Apyx Medical Corporation ( NASDAQ:APYX ) shareholders today, when the analysts...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Apyx Medical guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 26 | 56 | -9 | 36 | 3 |
| 31 Dec 25 | 53 | -11 | 36 | 3 |
| 30 Sep 25 | 48 | -15 | 36 | 4 |
| 30 Jun 25 | 47 | -17 | 37 | 4 |
| 31 Mar 25 | 47 | -20 | 40 | 4 |
| 31 Dec 24 | 48 | -23 | 43 | 5 |
| 30 Sep 24 | 49 | -28 | 46 | 5 |
| 30 Jun 24 | 49 | -28 | 47 | 6 |
| 31 Mar 24 | 50 | -23 | 48 | 6 |
| 31 Dec 23 | 52 | -19 | 48 | 5 |
| 30 Sep 23 | 50 | -15 | 48 | 5 |
| 30 Jun 23 | 47 | -16 | 48 | 5 |
| 31 Mar 23 | 44 | -21 | 47 | 5 |
| 31 Dec 22 | 45 | -23 | 48 | 5 |
| 30 Sep 22 | 49 | -19 | 48 | 4 |
| 30 Jun 22 | 51 | -18 | 48 | 4 |
| 31 Mar 22 | 52 | -16 | 47 | 4 |
| 31 Dec 21 | 49 | -15 | 44 | 4 |
| 30 Sep 21 | 43 | -15 | 40 | 4 |
| 30 Jun 21 | 38 | -14 | 37 | 4 |
| 31 Mar 21 | 31 | -15 | 34 | 4 |
| 31 Dec 20 | 28 | -12 | 34 | 4 |
| 30 Sep 20 | 25 | -16 | 34 | 4 |
| 30 Jun 20 | 25 | -16 | 35 | 4 |
| 31 Mar 20 | 28 | -16 | 36 | 4 |
| 31 Dec 19 | 28 | -20 | 35 | 4 |
| 30 Sep 19 | 26 | -18 | 34 | 3 |
| 30 Jun 19 | 22 | -15 | 29 | 3 |
| 31 Mar 19 | 19 | -14 | 26 | 3 |
| 31 Dec 18 | 17 | -11 | 22 | 3 |
| 30 Sep 18 | 14 | -10 | 18 | 2 |
| 30 Jun 18 | 13 | -12 | 17 | 2 |
| 31 Mar 18 | 5 | -15 | 17 | 2 |
| 31 Dec 17 | 10 | -14 | 17 | 2 |
| 30 Sep 17 | -12 | -19 | 15 | 1 |
| 30 Jun 17 | -4 | -17 | 15 | 1 |
| 31 Mar 17 | 37 | -4 | 20 | 3 |
| 31 Dec 16 | 9 | -12 | 15 | 1 |
| 30 Sep 16 | 35 | -5 | 18 | 3 |
| 30 Jun 16 | 33 | -5 | 18 | 2 |
| 31 Mar 16 | 31 | -6 | 18 | 2 |
| 31 Dec 15 | 30 | 8 | 17 | 2 |
| 30 Sep 15 | 29 | 4 | 17 | 2 |
| 30 Jun 15 | 28 | 3 | 16 | 2 |
Guadagni di qualità: APYX al momento non è redditizia.
Margine di profitto in crescita: APYX al momento non è redditizia.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: APYX non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 1.2% all'anno.
Accelerare la crescita: Impossibile confrontare la crescita degli utili di APYX nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia
Guadagni vs Settore: APYX non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Medical Equipment ( 14.8% ).
Rendimento del capitale proprio
ROE elevato: APYX ha un Return on Equity negativo ( -69.35% ), in quanto al momento non è redditizio.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/03 09:49 |
| Prezzo dell'azione a fine giornata | 2026/06/03 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Apyx Medical Corporation è coperta da 7 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Michael Gorman | BTIG |
| Sam Eiber | BTIG |
| David Turkaly | Citizens JMP Securities, LLC |